

STATEMENT



COMPENSATION CLAIM RE: MAREVAN® Batch Number 35222 RECALL

GSK New Zealand received the decision today (26 September 2011) from District Court Judge GA Andree Wilten on the compensation case related to costs incurred by Ian Johnson Pharmacy during the Marevan Recall .

Whilst we are pleased the value of the claim has been significantly diluted by Judge Wilten's decision GSK is disappointed with this outcome as it has broad, long lasting implications for patient safety in urgent recall situations.

GSK is reviewing the full judgement and will form a view on whether to appeal. We will also consult with regulatory authorities and other industry members on the implications of this judgement and consider options going forward.

Compensation claims for a medicine recall which have been initiated because of concern for patient safety are a complex issue and must be considered in the broader industry context . Setting compensation precedents will have a significant effect on the healthcare industry. Keeping the patient safe is the key concern in any recall situation, and this cannot be compromised while pharmacists and manufacturers negotiate service fees.

The Pharmacy Guild has suggested there is a case for claiming compensation for administrative time or counselling during a recall. However, the common understanding is that this is normally covered by the service fee paid by the government and there is no legal or regulatory requirement to provide additional compensation.

GSK replaced the Marevan® (warfarin) 3mg tablets free of charge to patients and paid direct 'out of pocket' expenses.

GSK's primary concern with the Marevan® (warfarin) 3mg product recall was protecting patient and public safety. GSK sincerely appreciates the efforts of pharmacists in helping to ensure the Marevan recall was undertaken quickly and effectively. We know this placed some pressure on the healthcare community and appreciate the professional manner in which it was undertaken.

Ends

Media Enquiries

Lisa Maguire, Corporate Affairs GlaxoSmithKline

Office: +61 3 9721 6637

Mobile: +61 449 950 745

STATEMENT



About MAREVAN

MAREVAN® is an anticoagulant treatment used widely in New Zealand to thin blood to help prevent blood clots.

MAREVAN is an anticoagulant belonging to a class of drug called coumarins or vitamin K antagonists. MAREVAN works by antagonising vitamin K in blood (which is needed to help blood clot), therefore inhibiting the formation of clotting factors II, VII, IX and X. It slows the clotting time of the blood. Higher levels of warfarin in the body means slower clotting time.

MAREVAN can be used for different indications (medical conditions).

For more information refer to the MAREVAN Data Sheet or the MAREVAN Consumer Medicine Information on the Medsafe website at www.medsafe.govt.nz.

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.nz

-Ends-